Global Cancer Janus Kinase Inhibitors Market Landscape Explored by Kuick Research in Its New Report Recently Added at MarketPublishers.com
26 Oct 2017 • by Natalie Aster
LONDON – Introduction of modern cancer treatment options like targeted therapy and immunotherapy has revolutionised the landscape of the cancer management. Amidst two modern therapies, targeted therapies have demonstrated remarkable growth in a very short period of time. The targeted therapies developed at a swift pace and gained much importance in the world’s market for cancer therapeutics owing to their advantages over conventional therapies such as higher safety and efficiency. The only challenges for targeted therapies was that only a few targets were available for the development of cancer therapeutics. However, high efficiency of targeted therapeutics for cancer encouraged the demand for outlining novel targets.
Janus kinase inhibitors (a.k.a. JAK inhibitors) have emerged as a novel potential candidate and growth frontier for different stakeholders engaged in the research and development of cancer drugs and therapeutic options. Presently, there is just one commercially available drug based on janus kinase inhibitors. However, 27 drugs are currently in various phases of clinical development; the majority of drugs are in preclinical phase (13 drugs).
JAK/STAT inhibitor is the latest invention in the sphere of targeted therapies is viewed as the best available therapeutic option for cancer. Over five JAK/STAT inhibitors are anticipated to enter the cancer therapeutic market in the coming decade. The development of JAK/STAT inhibitors had so impressive success in the past 5 years, that a great economic success of this class of drugs is predicted in the foreseeable future.
New research publication “Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” worked out by Kuick Research provides in-depth insights into the clenical and non-clinical landscape of the world’s cancer janus kinase inhibitor market. It touches upon the recent development and commercialisation trends, describes the role of JAK/STAT pathway in tumor formation, evaluates the JAK/STAT inhibitors’ potential in cancer anagement, examines the mechanism of action of JAK/STAT inhibitors, reviews the exhisting JAK/STAT inhibitors and presents in-depth insights into the drugs pipeline. Moreover, the report sheds light on the JAK/STAT inhibitor therapy prices, scrutinises the market dynamics, uncovers relevant info on the companies engaged in this field and also presents a comprehensive future outlook through 2023.
Follow Kuick Research page to find many other research reports prepared by the publisher.